Combining Abiraterone with Steroids

This discussion explores the differences in the effects of abiraterone formulations when combined with prednisone or methylprednisolone.

EP: 1.Expert Perspective on the Expanding Treatment Landscape in mCRPC

EP: 2.The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC

EP: 3.Management of Comment Adverse Effects Associated with mCRPC Therapies

EP: 4.Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

EP: 5.Overview of Abiraterone and the Differences Between Formulations

Now Viewing

EP: 6.Combining Abiraterone with Steroids

EP: 7.The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies

EP: 8.Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone

EP: 9.Dosing and Administration Considerations for Abiraterone Formulations

EP: 10.Access Challenges Regarding the Use of Abiraterone in Patients With mCRPC

EP: 11.Future Directions in mCRPC

• How do these formulations differ when combined with prednisone or methylprednisolone?

Related Videos

Related Content

Advertisement

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell

New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.

Related Content

Advertisement

May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke

Initial study results may be available as soon as the first half of 2026.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell

New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.

April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor

More than 80% of patients in both groups had a full recovery of testosterone.